vrijdag 2 september 2011

New Cancer Treatment

'New anti-cancer virus' shows potentials in Anti-Cancer Treatment


An engineered virus, injected into the blood, can selectively target cancer cells throughout the body in what researchers have labeled a medical first.
The virus attacked only tumors, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.Researchers said the findings could one day "truly transform" therapies.Cancer specialists said using viruses showed "real promise".

Using viruses to attack cancers is not a new concept, but they have needed to be injected directly into tumors in order to evade the immune system.

Smallpox to cancer
Scientists modified the vaccinia virus, which is more famous for being used to develop a smallpox vaccine.
The virus, named JX-594, is dependent upon a chemical pathway, common in some cancers, in order to replicate.It was injected at different doses into the blood of 23 patients with cancers which had spread to multiple organs in the body.In the eight patients receiving the highest dose, seven had the virus replicating in their tumors, but not in healthy tissue.Prof John Bell, lead researcher and from the University of Ottawa, said: "We are very excited because this is the first time in medical history that a viral therapy has been shown to consistently and selectively replicate in cancer tissue after intravenous infusion in humans."Intravenous delivery is crucial for cancer treatment because it allows us to target tumors throughout the body as opposed to just those that we can directly inject." Infection prevented further tumor growth in six patients for a time. However, the virus did not cure cancer. Patients were given only one dose of the virus as the trial was designed to test the safety of the virus.It is thought that the virus could be used to deliver treatments directly to cancerous cells in high concentrations. Prof Bell acknowledges that the research is still in the very early stages, but he said: "I believe that someday, viruses and other biological therapies could truly transform our approach for treating cancer."
Cancer Research UK's Prof Nick Lemoine, also director of Barts Cancer Institute, said: "Viruses that multiply in just tumor cells - avoiding healthy cells - are showing real promise as a new biological approach to target hard-to-treat cancers.
"This new study is important because it shows that a virus previously used safely to vaccinate against smallpox in millions of people can now be modified to reach cancers through the bloodstream - even after cancer has spread widely through the patient's body.
"It is particularly encouraging that responses were seen even in tumors like mesothelioma, a cancer which can be particularly hard to treat."


A Major step forward in the treatment of Cancer

Dr. Harry Spoelstra MD. 



zondag 24 juli 2011

Facebook

  FACEBOOK use leads to Healthcare reform in Taiwan.
(The Lancet) 

Facebook use leads to health-care reform in Taiwan. By - Shabbir Syed Abdul, Che-Wei Lin, Jeremiah Scholl, Luis Fernandez-Luque, Wen-Shan Jian, Min-Huei Hsu, Der-Ming Liou, Yu-Chuan Li
Facebook use leads to health-care reform in Taiwan : The Lancet July 2011

Constructieve aanval ingezet met positief resultaat. Hoe lang gaat het duren voordat wij als burgers via een medium gelijk FaceBook gaan participeren in wetgevende discussies. De Nieuwe Democratie?

Volg ons op Facebook: Therapeutisch Vasculair Centrum, Dr. Harry Spoelstra


dinsdag 19 juli 2011

Spatader operaties: Privé consultatie of in Ziekenhuis?

64% of CX delegates in favour of office-based vein practice



http://cxcontent.comrz.com/AfcIcon/Icons/Blank.gif


Delegates voted in favour of office-based vein practice for the treatment of varicose veins in a debate at CX33. The audience backed Ian Franklin, Imperial College, London, UK, with 64% of the votes, against 36% for Tim Lees, Newcastle, UK, who spoke against the motion “Office-based vein practice wins and should do so.”

Franklin, director of the CX Office-Based Vein Practice Course, told delegates that office vein practice “Is better for patients because it is quicker, everyone can be treated in a single visit, requires minimum time off work and is less disruptive. It is also much more applicable for people who used to be excluded from the operating theatre and, in many settings, it is more cost-effective.”
Franklin noted that, according to NHS figures, the number of endoluminal treatments have shown a steady increase from 2006 to 2009 compared to surgical treatments, which have declined progressively. “So many changes are happening right now and of course some of the endoluminal treatments were happening in the operating theatre, but the big jump came when it was done outside a clinic-based setting,” he said.


Het Therapeutisch Vasculair Centrum schaart zich achter deze grote meerderheid. Reeds enkele jaren is dit ook ons beleid. Hierdoor hebben wij al een grote ervaring in de behandeling van Veneuze pathologie buiten het Ziekenhuis. Wij zijn het dan ook eens met de leden van het CX33 congres, dat dit enkel voordelen heeft voor de patiënten en goedkoper is voor de Maatschappij.

Dr. Harry Spoelstra